medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2002; 1 (4)


Genomic medicine in Mexico. Applications of gene therapy for cirrhosis reversion

Armendariz-Borunda J

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 169-174
Archivo PDF: 54.50 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gene therapy clinical trials. The journal of gene medicine. www.wiley.co.uk/genmed.

  2. Kay M, Liu D, Hoogerbrugge P. Gene Therapy. Proc Natl Acad Sci USA 1997; 94: 12744-12746.

  3. Hacein-Bey- S, Le Deist F, Carlier F, Bouneaud C, Christophe Hue Ch, De Villartay J, Thrasher A, et. al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Eng J Med April 2002; 346(16): 1185-1193.

  4. Kay M, Manno C, Ragni M, Larson P, Couto L, Mcclelland A, Glader B, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics 2000; 24: 257-261.

  5. Hacein-Bey FF, Cavazzana-Calvo M. Gene theraphy of severe combined immunodeficiencies. Nat Rev Immunol 2002; 2(8): 615-21.

  6. Porada Ch, Tran N, Eglitis M, Moen R, Troutman L, Flake A, Zhao Y, et al. In utero gene therpay: Transfer and long-term expression of the bacterial neo gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Human Gene Therapy 1998; 9: 1571-1585.

  7. Zanjani E, Anderson W. Prospects for in utero human gene therapy. Science 1999; 285: 2084-2088.

  8. Zern M, Kresina T. Hepatic drug delivery and gene therapy. Hepatology 1997; 25(2): 484-491.

  9. Ferry N, Heard J. Liver-directed gene transfer vectors. Human Gene Therapy 1998; 9: 1975-1978.

  10. Martinez-Fong D, Mullersman J, Purchio A, Armendariz-Borunda J, Martinez-Hernandez A. Nonenzymatic glycosylation of poly-L-lisine: A new tool for targeted gene delivery. Hepatology 1994; 20(6): 1602-1608.

  11. De Godoy J, Malafosse R, Fabre M, Mitchell C, Mehtali M, Houssin D, Soubrane O. A preclinical model of hepatocyte gene transfer: the in vivo, in situ perfused rat liver. Gene Therapy 2000; 7: 1816-1823.

  12. Bataller R, Brenner D. Hepatic stellate cells as a target for the treatment of liver fibrosis. Seminars in Liver Disease 2001; 21(3): 437-451.

  13. Kafr T. Lentivirus vectors: difficulties and hopes before clinical trials. Curr Opin Mol Ther Aug. 2001; 3(4): 316-26.

  14. Russell D, Miller AD. Foamy virus vectors. Journal of Virology 1996; 70(1): 217-222.

  15. Olivarez E, Hollis R, Chalberg T, Meuse L, Kay M, Calos M. Site specific genomic integration produces therapeutic factor IX levels in mice. Nature Biotechnology 2001; 20: 1124-1128.

  16. Stephen S, Ehrhardt, A, Giehm J, Meuse L, Pham T, Kay M. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nature Biotechnology 2002; 20: 999-1005.

  17. Hartigan-O´Connor D, Amalafitano A, Chamberlain J. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. Journal of Virology 1999; 73(9): 7835-7841.

  18. Liu F, Huang L. Development of non-viral vectors for systemic gene delivery. Journal of Controlled Release 2002; 78: 259-266.

  19. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-1258.

  20. Yu, Q., Shao, R., Quian, HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105(6): 741-748.

  21. UesugiT, Froh M, Arteel GE, Bradford BU, Gabele E, Wheeler MD, Thurman RG. Delivery of IkB superrepresor gene with adenovirus reduces early alcohol- induced liver injury in rats. Hepatology 2001; 34: 1149-1157.

  22. Hecht N, Pappo O, Shouval D, Rose-John S, Galun E, Axelrod JH. Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Molecular Therapy 2001; 3(5): 683-687.

  23. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 96: 2345-2349.

  24. Aguilar L, Aguilar-Cordova E, Ando D, Armendariz-Borunda J, Brud P, Butler E, Carter B, et al. A Prescription for gene therapy. Molecular Therapy 2000; 1(5): 385-388.

  25. Garcia-Bañuelos J, Siller-Lopez F, Miranda A, Aguilar LK, Aguilar-Cordova E, Armendariz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Therapy 2002; 9: 127-134.

  26. Ueki T, Kaneda Y, Tsuitsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-230.

  27. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A, Segura A, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Molecular Therapy 2000; 2(6): 545-551.

  28. Siller F, Salgado S, Sandoval A , Salazar A, Garcia J, Vera J, Galvan FJ, Juan Armendariz-Borunda. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology. In press.




2020     |     www.medigraphic.com